Pay into $2bn antibiotics fund, O'Neill tells big pharma
This article was originally published in Scrip
Executive Summary
In its third report, the Jim O'Neill Review on Antimicrobial Resistance (AMR) is making some bold proposals and pointing to big pharma to act with a long-term vision in mind.